Results: 1-20 |
Results: 20

Authors: Herr, HW Donat, SM Bajorin, DF
Citation: Hw. Herr et al., Bladder cancer, the limits of surgical excision - when/how much?, UROL ONCOL, 6(5), 2001, pp. 221-224

Authors: Mazumdar, M Bajorin, DF Bacik, J Higgins, G Motzer, RJ Bosl, GJ
Citation: M. Mazumdar et al., Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy, J CL ONCOL, 19(9), 2001, pp. 2534-2541

Authors: Vuky, J Bains, M Bacik, J Higgins, G Bajorin, DF Mazumdar, M Bosl, GJ Motzer, RJ
Citation: J. Vuky et al., Role of postchemotherapy adjunctive surgery in the management of patients with nonseminoma arising from the mediastinum, J CL ONCOL, 19(3), 2001, pp. 682-688

Authors: Bajorin, DF
Citation: Df. Bajorin, Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer, J CL ONCOL, 19(18), 2001, pp. 17S-20S

Authors: Herr, HW Donat, SM Bajorin, DF
Citation: Hw. Herr et al., Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer, J UROL, 165(3), 2001, pp. 811-814

Authors: Bajorin, DF
Citation: Df. Bajorin, Exploring sequenced chemotherapy regimens in the treatment of transitionalcell carcinoma of the urothelial tract, EUR J CANC, 36, 2000, pp. S26-S29

Authors: Bajorin, DF
Citation: Df. Bajorin, Paclitaxel in the treatment of advanced urothelial cancer, ONCOLOGY-NY, 14(1), 2000, pp. 43

Authors: Dodd, PM McCaffrey, JA Mazumdar, M Scher, H Higgins, G Boyle, MG Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer, CANCER INV, 18(7), 2000, pp. 626-634

Authors: Rabbani, F Sheinfeld, J Farivar-Mohseni, H Leon, A Rentzepis, MJ Reuter, VE Herr, HW McCaffrey, JA Motzer, RJ Bajorin, DF Bosl, GJ
Citation: F. Rabbani et al., Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: Pattern and prognostic factors for relapse, J CL ONCOL, 19(7), 2000, pp. 2020-2025

Authors: Motzer, RJ Mazumdar, M Sheinfeld, J Bajorin, DF Macapinlac, HA Bains, M Reich, L Flombaum, C Mariani, T Tong, WP Bosl, GJ
Citation: Rj. Motzer et al., Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients, J CL ONCOL, 18(6), 2000, pp. 1173-1180

Authors: Dodd, PM McCaffrey, JA Hilton, S Mazumdar, M Herr, H Kelly, WK Icasiano, E Boyle, MG Bajorin, DF
Citation: Pm. Dodd et al., Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract, J CL ONCOL, 18(4), 2000, pp. 840-846

Authors: Dodd, PM McCaffrey, JA Mazumdar, M Icasiano, E Higgins, G Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma, INV NEW DR, 18(3), 2000, pp. 247-251

Authors: Vuky, J McCaffrey, J Ginsberg, M Mariani, T Bajorin, DF Bosl, GJ Motzer, RJ
Citation: J. Vuky et al., Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors, INV NEW DR, 18(3), 2000, pp. 265-267

Authors: Steyerberg, EW Keizer, HJ Sleijfer, DT Fossa, SD Bajorin, DF Gerl, A de Wit, R Kirkels, WJ Koops, HS Habbema, JDF
Citation: Ew. Steyerberg et al., Retroperitoneal metastases in testicular cancer: Role of CT measurements of residual masses in decision making for resection after chemotherapy, RADIOLOGY, 215(2), 2000, pp. 437-444

Authors: Bajorin, DF McCaffrey, JA Dodd, PM Hilton, S Mazumdar, M Kelly, WK Herrr, H Scher, HI Icasiano, E Higgins, G
Citation: Df. Bajorin et al., Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract - Final report of a phase II trial evaluating two dosing schedules, CANCER, 88(7), 2000, pp. 1671-1678

Authors: Cozzi, PJ Bajorin, DF Tong, W Nguyen, H Scott, J Heston, WDW Dalbagni, G
Citation: Pj. Cozzi et al., Toxicology and pharmacokinetics of intravesical gemcitabine: A preclinicalstudy in dogs, CLIN CANC R, 5(9), 1999, pp. 2629-2637

Authors: Dodd, PM McCaffrey, JA Herr, H Mazumdar, M Bacik, J Higgins, G Boyle, MG Scher, HI Bajorin, DF
Citation: Pm. Dodd et al., Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, J CL ONCOL, 17(8), 1999, pp. 2546-2552

Authors: Bajorin, DF Dodd, PM Mazumdar, M Fazzari, M McCaffrey, JA Scher, HI Herr, H Higgins, G Boyle, MG
Citation: Df. Bajorin et al., Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy, J CL ONCOL, 17(10), 1999, pp. 3173-3181

Authors: Herr, HW Bajorin, DF Scher, HI Cordon-Cardo, C Reuter, VE
Citation: Hw. Herr et al., Can p53 help select patients with invasive bladder cancer for bladder preservation?, J UROL, 161(1), 1999, pp. 20-22

Authors: Dodd, PM McCaffrey, JA Mazumdar, M Scher, H Vlamis, V Higgins, G Herr, H Bajorin, DF
Citation: Pm. Dodd et al., Phase II trial of intermediate dose methotrexate in combination with vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma, CANCER, 85(5), 1999, pp. 1145-1150
Risultati: 1-20 |